Security key
07782B104
BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share (BLTE)
CUSIP: 07782B104
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Ordinary shares, par value US$0.0001 per share
- Total 13F shares
- 1,686
- Total 13F value
- $259,619
- Share change
- -21
- SEC-reported price per share
- $153.99
- Number of holders
- 1
- Value change
- -$3,234
- Number of sells
- 1
- Shares outstanding
- 40,449,516
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
BLTE full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
BELITE BIO, INC SEC filings
BELITE BIO, INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 07782B104
Recent filing periods:
Ownership snapshot
Top reported holders of BLTE - BELITE BIO, INC - Ordinary shares, par value US$0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Lin Bioscience Internatio...
Disclosed value leader
Lin Bioscience Internatio...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 54%
13D/G row: Lin Bioscience International Ltd.
Showing 1-6 of 15 holder rows.
Quick read
Lin Bioscience International Ltd. leads the comparable SEC ownership view at 54%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Lin Bioscience International Ltd.'s linked filing trail.
Comparable ownership
Top 5
Lin Bioscience International Ltd.
54%
Darwin Global Management, Ltd.
8.1%
Yu-Hsin Lin
3.1%
Paradigm Biocapital Advisors LP
2.8%
UBS Group AG
1.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Lin Bioscience International Ltd. |
13D/G
|
54%
|
$1,065,034,885
17,095,263 shares
|
$0 | 31 Dec 2024 |
| Darwin Global Management, Ltd. |
13D/G
13F
Company
|
8.1%
|
$479,467,205
3,027,704 shares
|
+$65,024,200 | 31 Dec 2025 |
| Yu-Hsin Lin |
13D/G
3/4/5
Chief Executive Officer, Director
|
3.1%
|
$212,905,624
1,253,935 shares
|
-$175,415,992 | 31 Mar 2026 |
| Paradigm Biocapital Advisors LP |
13F
Company
|
2.8%
|
$177,741,161
1,114,784 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
1.9%
|
$122,507,159
768,359 shares
|
— | 31 Mar 2026 |
| RTW INVESTMENTS, LP |
13F
Company
|
1.8%
|
$114,052,534
715,332 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
1,686
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
75
Q2 2026 holders
1
Holder diff
-74
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend